EGFR mutations cause abnormal activation of the downstream JAK/STAT3 signalling pathway, leading to increased expression of phosphorylated STAT3, followed by abnormal tumor growth, angiogenesis, invasion, and metastasis. Here, STAT3 is linked to neoplasm.